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&e 5′ untranslated region (5′UTR) of rodent hepacivirus (RHV) and pegivirus (RPgV) contains sequence homology to the HCV
type III internal ribosome entry sites (IRES). Utilizing a monocistronic expression vector with an RNA polymerase I promoter to
drive transcription, we show cell-specific IRES translation and regions within the IRES required for full functionality. Focusing on
RHV, we further pseudotyped lentivirus with RHV and showed cell surface expression of the envelope proteins and transduction
of murine hepatocytes and we then constructed full-length RHV and RPgV replicons with reporter genes. Using the replicon
system, we show that the RHV NS3-4A protease cleaves a mitochondrial antiviral signaling protein reporter. However, liver-
derived cells did not readily support the complete viral life cycle.
1. Introduction
&e hepatitis C virus (HCV) infects more than 71 million
people worldwide [1], which can lead to liver failure and
hepatocellular carcinoma and presents a major global health
burden. While the introduction of new direct-acting anti-
viral drugs (DAAs) has improved treatment response rates
and heralded a new era of HCV treatment [2], the cost and
availability of DAAs along with drug resistance and chronic/
nonreversible liver damage due to late onset of symptoms
and delayed treatment initiation after HCV infection remain
an issue [3]. A small animal model for HCV would allow for
the testing of vaccines which could potentially solve these
problems.
HCVwas discovered in humans 20 years ago [4] but for a
long time, researchers failed to identify an animal viral
homologue.&is all changed with the use of high throughput
deep sequencing, which has shed light on the evolutionary
origins of the virus. &e first HCV homologue was dis-
covered in 2011 in canines [5] and was quickly followed by
the discovery of homologues in rodents [6, 7], equine [8, 9],
primates [10], bovine [11, 12], and then, the first non-
mammalian species, sharks [13].
&e rodent HCV homologues were termed rodent
hepaciviruses (RHV) and were first identified in deer mice
(Peromyscus maniculatus), a species known to carry han-
tavirus, desert woodrats (Neotoma lepida), and hispid pocket
mice (Chaetodipus hispidus) [7]. &e same year RHV was
described in European bank voles (Myodes glareolus) and
South African four-striped mice (Rhabdomys pumilio) [6].
&is was succeeded by the discovery of an RHV from
Norway rats (Rattus norvegicus) in New York City [14].
&e subsequently discovered RHV (RHV-rn1) from
Norway rats was used to make a small animal model for
hepaciviral infection, utilising a reverse genetics approach.
In this system, the researchers showed its hepatotropic
replication in inbred and outbred rat strains [15]. Emulating
HCV infection, they also showed that persistent infection
leads to gradual liver damage and that the HCV antiviral
drug sofosbuvir suppresses replication of RHV-rn1. &is
model can be used to study the mechanisms of HCV per-
sistence, immunity, and pathogenesis.
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&ough rats are the usual hosts of RHV-rn1, it has also
been shown that the virus is capable of establishing a per-
sistent infection in immunocompromised mice lacking type
I interferon and adaptive immunity [16]. However, im-
munocompetent mice clear the virus in a few weeks. Because
this mouse model only results in an acute infection, a fully
immunocompetent mouse model in which a chronic in-
fection and downstream liver damage can be established is
still in need. Additionally, the availability of knockout mice
would aid the study of the pathogenesis of HCV related liver
damage.
While these studies could lead the way to future vaccines,
they also present the possibility of zoonotic sources of HCV
infection in humans [17]. &e genomes of RHV encode for a
polyprotein that is predicted to be cleaved into 10 proteins,
as with HCV, but shows a 66–77% amino acid divergence
from HCV in the structural genes [7, 18]; therefore, tropism
and pathogenicity may also differ between the viruses. In
particular, the 5′ untranslated regions (UTRs) of RHV are
highly divergent from the corresponding regions of HCV,
and there is a large difference between the different rodent
clades (RHV, RHV1, RHV2, RHV3, and RHV-rn1).
&e high-level expression of mir-122 in liver cells allows
HCV, containing two mir-122 target sequences in the
5′UTR, to replicate and is one reason for HCV hepato-
tropism [19]. Similarly, the RHV (NC_021153) found in deer
mice contains one suchmir-122 target sequence in its 5′UTR
[7] suggesting liver cell specificity and further has a 200 nt
sequence with no homology to other hepaciviruses 5′UTRs.
&e RHV-1 (KC411777)) 5′UTR contains structural ele-
ments typical of both pegi- and HCV-like IRES and contains
one mir-122 target region, while RHV-1 and RHV-2
(KC411784) are identical in structure and only contain a few
nucleotide exchanges, with RHV-3 (KC411807) and RHV-
rn1 being more similar to typical HCV-like IRES structures
[6, 15] (Figure 1).
Along with RHV, a rodent pegivirus (RPgV) was also
discovered in white-throated wood rats (Neotoma albigula)
[7]. Pegiviruses are a new genus of the family of the Fla-
viviridae, encompassing the human GBV-A, GBV-C/HGV/
HPgV-1, GBV-D and HPgV-2 viruses. &ese pegiviruses
are considered to be nonpathogenic and in the case of
HPgV has even been reported to be beneficial in coin-
fections with HIV or Ebola [20–22]. However, two pegi-
viruses were discovered in equine. &e first, &eiler’s
disease-associated virus (TDAV), is suspected to be the
causative agent for an outbreak of acute hepatic disease
occurring on a horse farm [23]. &e second, equine
pegivirus (EPgV), like the human pegiviruses, is considered
to be nonpathogenic [24].
&e viral RNA structures play important roles in both
translation and replication. Specifically, the 5′UTR
containing the IRES promotes the initiation of protein
synthesis in a cap-independent manner. IRES’s are di-
verse in sequence and structure and these differences
contribute to tropism; the focus of this study is to assess
how these differences in the 5′UTRs of RHV and RPgV
affect translation and to establish a reverse genetics
system utilizing the RNA polymerase I promoter and
terminator in a DNA transfection system [25, 26] to allow
for quick and easy mutation and screening.
2. Materials and Methods
Cells. Hepa1-6 (ATCC® CRL-1830™), MEFs IRF3
-/-,
NIH 3T3 (ATCC® CRL-1658™), BHK-21 (ATCC®
CCL-10™), HEK 293T (ATCC® CRL-11268™), Huh-
7.5-RFP-MAVS from Dr Charles M Rice, HepG2
(ATCC® HB-8065™) and Vero cells (ATCC® CCL-
81™) were cultured in DMEM (Sigma-Aldrich), 10%
FBS and 1% penicillin-streptomycin.
Plasmid Construction. Monocistronic reporter plas-
mids containing viral 5′UTR were constructed in
pUC19. First, pUC19 was digested with EcoR1 and
HIndIII (NEB), and then a minimal RNA polymerase I
(RNA Pol I) promoter and terminator (synthesised by
Twist Biosciences) was inserted into the digested
plasmid by In-Fusion cloning (Takara Bio); this plas-
mid was named pOLI (Figure S1A).
&e plasmid pOLI was linearized with PpuMI. Viral 5′
and 3″ UTR (synthesised by Twist Biosciences) (HCV
IRES taken from pFR_HCV_xb (Addgene)) along
mCitrine were cloned into the linearized pOLI by In-
Fusion cloning (Takara Bio) (Figure S1B). Deletions
and additions to the monocistronic reporter plasmids
were created by PCR and In-Fusion cloning (Takara
Bio).
Plasmids containing viral structural genes were con-
structed in pUC19 by In-Fusion cloning (Takara Bio)
using hepacivirus CE1E2 region (synthesised by Twist
Biosciences), along with a CMV promoter and BGH
polyA (Figure S1C). Flag tag and c-Myc tag sequences
were inserted into this plasmid by PCR and In-Fusion
cloning (Takara Bio); this plasmid was named pCMy-
cE1E2Flag. &e capsid gene was deleted from pCMy-
cE1E2Flag by PCR and In-Fusion cloning (Takara Bio)
resulting in the plasmid pE1E2Flag.
To construct plasmids containing full-length RHV1
and RPgV viral genomes, the respective monocistronic
vector (pOLI.IRES.Cirtine) was PCR linearized, and
gene fragments, 1.5–2 kb (synthesised by Twist Bio-
sciences), covering the full-length viral coding region
were then cloned in by In-Fusion cloning (Takara Bio)
replacing mCitrine. &e plasmids were named
pOLI.RHV1 and pOLI.RPGV (Figure S1D).
For constructing a reporter plasmid, mScarlet-BSD
(synthesised by Twist Biosciences) was cloned into the
plasmid containing the full-length virus in-between
NS5A and NS5B, while also duplicating the cleavage
sequence by In-Fusion cloning (Takara Bio). &ese
plasmids were named pOLI.RHV1.SB and
pOLI.RPgV.SB (Figure S1E).
Transfection. All transfections were carried out using
Lipofectamine® LTX with Plus™ Reagent (&ermo
Fisher Scientific) in Opti-MEM (Gibco) according to
the manufacturer’s specifications.











































































Figure 1: Predicted RNA secondary structures within HCV, RHV, RHV1, RHV2, RHV3, RHV-rn1, and RPgV 5′ UTR. &e sequence
corresponding to themir-122 binding sites within the 5′UTR is highlighted in orange; the first binding sites are represented by filled circles and
the second by the outline. HCV contains twomir-122 binding sites and RHV, RHV1, and RHV-rn1 contain one predicted binding site. RHV2/3
and RPgV do not contain a mir-122 binding site. &e nucleotides corresponding to the AUG start codon are highlighted by filled green circles.
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Western Blot. Cells were lysed in RIPA buffer (150mm
NaCl, 50mm Tris/HCl pH 7.6, 1% Nonidet P40, 0.5%
sodium deoxycholate, and 5mm EDTA) supplemented
with cOmplete™ Protease Inhibitor Cocktail (Roche)
for 15min on ice. &e lysate was run on a 12% SDS-
Page and transferred to PVDF membrane (Bio-Rad).
Membranes were incubated for 1 hour in PBS with 5%
nonfat dry milk and then stained with primary and
subsequently secondary antibodies for 1 hour in PBS
with 1% nonfat dry milk. Immunocomplexes were
detected using an Odyssey® Fc Imaging System (LI-
COR Biosciences).
Intracellular Immunofluorescence. Cells were grown on
glass coverslips, washed with PBS prior to fixation in
formaldehyde (3.7% w/v in PBS) for 10min at room
temperature, permeabilized for 5min with 0.1% Triton
X-100 in PBS, and blocked with 3% BSA in PBS for
30min. Primary and secondary antibodies were diluted
in PBS containing 1% BSA, and cells were stained with
primary antibody for 1 hour, washed 3x with PBS, and
then stained with secondary antibody for 1 hour, fol-
lowed by staining with 0.1 µg/ml DAPI in PBS for 5min
and application of Prolong Gold Antifade reagent
(Invitrogen).
Extracellular. Cells were grown on glass coverslips,
incubated with PBS containing 4% FBS (Fetal Bovine
Serum) for 30min. Primary and secondary antibodies
were diluted in PBS containing 4% FBS, cells were
stained with primary antibody for 1 hour, washed 3x
with PBS, and then stained with secondary antibody for
1 hour. Cells were then stained with Wheat Germ
Agglutinin, Alexa Fluor™ 594 conjugate as per man-
ufacturers protocol. Cells were fixed in formaldehyde
(3.7% w/v in PBS) for 10min at room temperature,
permeabilized for 5min with 0.1% Triton X-100 in PBS,
and stained with 0.1 µg/ml DAPI in PBS for 5min
followed by application of Prolong Gold Antifade re-
agent (Invitrogen).
Images were acquired using a confocal microscope
(Leica specify type) and Z-stacks and analysed with
ImageJ.
Antibodies. Rat anti-DYKDDDDK (clone L5, Biol-
egend), mouse anti-c-myc (clone 9E11, Biolegend),
mouse anti-β-actin (clone 2F1-1, Biolegend), mouse J2
anti-dsRNA IgG2a (Sciscons), goat anti-rat IgG (H+ L)
Alexa Fluor 488 (Invitrogen), IRDye® 800CW goat
anti-rat IgG, and IRDye® 680RD donkey anti-mouse
IgG (LI-COR Biosciences).
Flow Cytometry. Single cell suspensions were generated
and kept in FACS buffer (2% FCS, 5mmEDTA in PBS).
Cells were analysed using a Gallios flow cytometer
(Beckman Coulter) and FlowJo software and gated on
viable cells using the live/dead fixable near-IR dead cell
stain kit (Invitrogen).
Lentivirus. Plates were seeded with HEK 293T in
DMEM and 3% FCS and then transfected with pLKO-
gfp (Addgene), pCMV∆R8.2 (Addgene), and either
pMD2.G (Addgene) or pE1E2 at a ratio of 1 :1:0.1,
respectively, using lipofectamine LTK (&ermo Fisher
Scientific) and Opti-mem (Gibco). At 6 hours after
transfection, media were replaced and 72 h after
transfection, supernatant was harvested and passed
through a 0.45 µm filter.
2.1. RNA Structure Prediction. &e RNA sequences sec-
ondary structure was predicted with RNA fold and visual-
ization was performed using force directed graph layout
(Forna); both are hosted on ViennaRNA Web services
(http://rna.tbi.univie.ac.at/forna/).
2.2. RNA Extraction and cDNA Generation. Cells from 24-
well plate were washed in PBS and resuspended in Trizol
(Sigma-Aldrich, USA), and RNA was isolated by iso-
propanol precipitation, washed with 70% ethanol, and
resuspended in DEPC-water. RNA was DNAse treated
(Invitrogen, Paisley, UK) and subjected to RT-PCR using
100 ng purified RNA. For RT-PCR, the high-capacity cDNA
archive Kit from Applied Biosystem (ABI PRISM, War-
rington, United Kingdom) was used according to the
specifications of the manufacturer.
2.3. Quantitative Real-Time PCR for Selected Genes.
Quantitative real-time PCR was performed using a Light
cycler 480 Real-Time PCR System (Roche Diagnostics) and
the LightCycler 480 probes master reaction mix (Roche
Diagnostics) following the manufacturer’s protocol. Data
analysis was performed with LightCycler 480 Software
(Roche Diagnostics). Oligonucleotides sequences used as
primers for quantitative real-time PCR and corresponding
probes were designed according to the guidance of the
Universal Probe library from Roche applied Science.
&ermal cycling started with HotStarTaq activation during
10min at 95°C. &ereafter, 45 cycles of amplification were
run consisting of 10 s at 95°C, 30 s 60°C, and 20 s of 72°C. A
negative control containing reagents only and serial dilu-
tions of cDNA was included in each run. Each sample was
measured as a triplicate and the average concentration was
used. For LightCycler analysis, expression of hypoxanthine
phosphoribosyltransferase gene (HPRT) was used for nor-
malization. Relative expression of samples was calculated by
the comparative cycling threshold method (ΔΔCT) and then
setting the samples transfected with HCV IRES as the
benchmark.
GeneBank Accession Numbers. RHV (Hepacivirus E),
NC_021153; RHV1 (Hepacivirus J), KC411777; RHV2 (Hep-
acivirus F), KC411784; RHV3 (Hepacivirus I), KC411807;
RHV-rn1 (Hepacivirus G), KX905133.1; RPgV, NC_021154.
3. Results
3.1. RHV and RPgV IRESs Are Functional in Rodent Cells.
To test viral IRES driven translation, a monocistronic
plasmid vector was constructed containing a minimal RNA
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polymerase I promoter in front of the full-length viral 5′
UTR followed by a fluorescent maker, the viral 3′ UTR, and
the RNA polymerase I terminator (Figure 2(a)). &e HCV
IRES was used as a positive control along with a control
plasmid containing a scrambled sequence in place of the
viral 5′ UTR. We constructed plasmids containing RHV,
RHV1, RHV2, RHV3, RHV-rn1, and RPgV 5′ UTR from
previously published sequences.
&ese plasmids were transfected into the murine hepa-
tocyte cell lineHepa1-6, with theHCV and RPgV IRES driving
the highest level of translation at 72 hours after transfection
with a mean fluorescence intensity (MFI) of 30, followed by
RHV1 and RHV2 with an MFI of 22 and 14, respectively.
RHV3 and RHV-rn1 IRES drove translation at a level only
slightly above background and RHV was not functional in
Hepa1-6 (Figure 2(b)). To further assess the level of RNA
transcripts of mCitrine within the cells, we preformed qRT-
PCR on transfected cells. &ere was no statistical difference in
the level of transcripts between HCV, RHV, RHV1, RHV2,
RHV3, RHV-rn1, RPgV, and the control plasmid containing a
scrambled sequence in place of the viral 5′UTR. &e other
control plasmid contains RHV1 5′UTR but no Pol I promoter
did yield a readily detectable level of RNA (Figure S2).
To further assess IRES function in murine cells, we tested
two murine embryonic fibroblasts cell lines, MEFs and NIH
3T3. Transfection of MEFs with the plasmids revealed that
RHV1 drove the highest level of translation at an MFI of 9
followed by RHV2 at an MFI of 5 (Figure 3(c)). HCV, RHV,
RHv3, RHV-rn1, and RPgV generated signals only slightly
above the negative control. In NIH3T3, the RPgV drove the
highest level of translation with an MFI of 17 followed by
HCV with an MFI of 7; again, RH1 and RHV2 were
functional but at low levels, and RHV, RHV3, and RHV-rn1
were not functional (Figure 3(d)).
&e viruses originate from different rodent species;
therefore, the baby hamster kidney cell line was tested to
assess if the IRESs are functional in this cell line. As with the
previous cell lines, the RPgV IRES drove high levels of
translation; also the RHV1 and RHV2 were capable of
driving high levels followed by HCV; again, the RHV,
RHV3, and RHV-rn1 were not functional (Figure 2(e)).
3.2.RHVandRPgVIRESsShowDifferingFunctions inHuman
Cell Lines. In the human hepatocyte cell line, Huh7.5 which
expresses high levels of mir122, and the RPgV IRES drives
the highest levels of translation followed by HCV and RHV2.
&e RHV-rn1 drove low levels of translation and, as with
murine cells, RHV and RHV3 did not yield any signal
(Figure 2(f )). Another human hepatocyte cell line, HepG2
that does not express mir122, was also used to test the IRES’s
function: in these cells, HCV drove the highest levels fol-
lowed by RPgV and RHV2, while the expressions from RHV,
RHV1, RHV3, or RHV-rn1 were at background level
(Figure 2(g)).
To investigate if the IRESs are functional in non-
hepatocyte cells lines, we used HEK 293Tand Vero cell lines.
In HEK 293T, the HCV IRES showed the highest level of
translation followed by the RPgV IRES and RHV2, while
that of RHV, RHV1, RHV3, and RHV-rn1 was at the lowest
level (Figure 2(h)). In Vero cells, the RPgV produced high
levels of translation, over twice that of HCV; RHV2 was the
only other IRES that was functional in these cells although at
a very low level when compared to RPgV (Figure 2(i)).
3.3. DeletionsAbrogate the Function of RHV1andRPgV IRES.
To further assess the structural requirements of RHV1 IRES
for full functionality, we made several different constructs.
&e first contained an additional 20 nucleotides of virus
sequences downstream of the start codon. When transfected
into Hepa1-6 cells, this construct did not lead to a difference
in the levels of translation in comparison with the construct
containing just the 5′ UTR. Two deletion constructs were
made; in RHVΔI, the 5′ three stem loops (Ia/b/c) were deleted
(Figure 3(a)). &is deletion decreased the IRES function by
90%. &e Va and Vb stem loops were deleted from RHV1ΔII
and again led to a decrease in function by 90% in the murine
hepatocyte cell line Hepa1-6 (Figure 3(c)).
For the RPgV IRES, we also added an additional 20
nucleotides of virus sequences downstream of the start
codon.&is again had no effect on the levels of translation in
comparison to the construct containing just the 5′ UTR. To
further assess the sequence required for driving translation,
three constructs were made with deletions, RPgVΔI and
RPgVΔII have deletions to the 5′ of the IRES with RPgVΔI
having the first two stem loops (Ia/b) and RPgVΔII three
stem loops deleted (Ia/b and II) (Figure 3(b)). RPgVΔIII has
two internal stem loops deleted (IIId/e). &e 5′ deletions to
RPGV had no effect on the levels of translation. However,
the internal deletions in RPgVΔIII led to a reduction in
translation of 53% (Figure 3(d)).
3.4. Expression of E1E2. Previous studies examining the
subcellular localization of HCV E1 and E2 used cells
transfected with a plasmid expressing the E1 and E2 proteins
[27]. &ese studies concluded that the HCV structural
proteins are expressed on the cell surface, based on im-
munofluorescence detection. In order to examine the lo-
calization of RHV structural proteins in an expression
system, we cloned the structural region (capsid-E1-E2) of
RHV into a plasmid containing the CMV promoter; we then
added the c-Myc tag to the 5′ end of the capsid protein and
the Flag tag to the 5′ end of the E2 protein following the
E1E2 cleavage sequence (Figure 4(a)).
HEK 293T cells were transfected with the vectors
pE1E2Flag or pCMycE1E2Flag and after 48 hours lysed for
SDS-PAGE. &e E2 protein was detected in cells transfected
with either expression vector using an anti-Flag tag antibody
(Figure 4(a)), and the capsid was detected in cells transfected
with the pCMycE1E2Flag expression vector using an anti-c-
Myc antibody. &e proteins detected were of the predicted
size, showing that posttranslational cleavage was complete.
In order to determine if the RHV glycoproteins
expressed from these vectors also exhibit an intracellular
colocalization, we examined transfected cells by immuno-
fluorescence for capsid and E2 expression; both were shown
to colocalize (Figure 4(b)). We also assessed if the envelope
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PolIP mCitrine5′UTR PolIT3′UTR
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31 ± 2.99 22 ± 1.56
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Figure 2: RHV and RPGV IRES activity in different cell types. Schematic of the monocistronic vectors used (a). Hepa1-6 (b), MEFs (c), NIH
3T3 (d), BHK-21 (e), Huh7.5 (f ), HEK 293T (h), and Vero (i) cells were transfected with the indicated plasmids. Cells were harvested and
analysed by flow cytometry at 48 h.p.t.; bar graphs show MFI for mCitrine (n≥ 8, mean± SEM of at least three independent experiments),
and representative FACS plots on the right of each graph numbers represent the MFI (mean± SEM). &e dashed line represents the
fluorescent output of the control plasmid containing a scrambled sequence in place of the viral 5′ UTR.
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protein was expressed on the cell surface. Staining with anti-
flag antibody to detect E2 indeed showed punctate staining
on the cell membrane and when combined with wheat germ
agglutinin to stain the cell membrane, it showed colocali-
zation with the flag antibody (Figure 4(c)). &is indicates
that a proportion of E2 is surface-expressed.
To determine if the surface-localized E1E2 could mediate
viral entry, we produced a GFP encoding lentivirus vector
pseudotyped with the RHV, RHV1, RHV2, and RHV3 E1E2
proteins by transfecting HEK 293T cells with pE1E2 and the
lentivirus backbone and packaging plasmid, and 72 h later
harvesting and filtering the supernatant. We then tested if the
E1E2-pseudotyped lentivirus vectors were entry-competent.
Supernatants from the cotransfected cells were applied to
Hepa1-6 cells and GFP reporter expression assayed 72h later.
RHV1 E1E2-pseudotyped lentivirus vectors gave rise to a
small number of GFP positive cells, when compared to VSVG
pseudotyped lentivirus. Lentivirus vectors pseudotyped with
RHV, RHV2, and RHV3 or lacking envelope glycoprotein
failed to give rise to any GFP positive cells (Figure 4(d)). &is
indicates that only RHV1 pseudotyped lentivirus vectors can
mediate viral entry in Hepa1-6 cells resulting in reporter gene
expression. &is data also indicates that surface-expressed
RHV1 E1E2 heterodimers are functional.
4. Discussion
&e five rodent hepacivirus IRESs we tested showed different
levels of ability to drive translation using in a monocistronic
vector across varying cell lines. While the use of a mono-
cistronic vector, utilizing RNA polymerase I, avoids the
potential of readthrough in comparison to bicistronic vec-
tors; its drawback is that we were not able to directly
compare expression levels between cell types due to their
difference in susceptibility to transfection. However, the
RHV, RHV3, and RHV-rn1 IRESs were either not functional
or drove expression at very low levels. &is comes as a
surprise as the RHV-rn1 virus has already been shown to
replicate in both mice and rats.
Both RHV1 and RHV2 drive high levels of translation in
murine hepatocytes, MEFs and BHK-21 cells. In human
hepatocytes, the RHV2 IRES outperformed RHV1 which is of
interest as they are similar in sequence and therefore are likely
to have a similar structure. In the case of RHV1, deleting the
predicted initial three stem loops abrogates IRES function,
suggesting that the full 5′UTR sequence is required to
maintain high levels of expression. Also, unlike HCV, where
previous studies have shown that the inclusion of 12–30 nt of
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Figure 3: Deletions to RHV1 and RPgV 5′ UTR abrogate IRES translation. Predicted RNA secondary structure of RHV1 (a) and RPgV (b).
Red circles indicate areas deleted from plasmids. Hepa1-6 cells were transfected with RHV1 (c) and RPgV (d) plasmids. Cells were harvested
and analysed by flow cytometry at 48 h.p.t. Bar graphs showMFI formCitrine (n≥ 8, mean± SEM of at least three independent experiments)
and representative FACS plots on the right of each graph; numbers represent the MFI (mean± SEM). &e dashed line represents the
fluorescent output of the control plasmid containing a scrambled sequence in place of the viral 5′ UTR.
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IRES activity [28], additional nucleotides from the core
protein of RHV1 did not increase transcription levels.
&e RPgV 5′UTR has little significant similarity with
any known pegivirus but drives high levels of expression
in all cell types tested. By deleting specific regions, we were
able to show that the initial 126 nt of the 5′UTR does not
contribute to IRES function and that stem loops IIId/e are
essential for maintaining high levels of expression. It
would be of significance in the future to confirm the
predicted structures of RPgV and RHV1 IRES’s poten-
tially using RNA SHAPE.
RHV1 structural genes (C, E1, and E2) expressed from
plasmid were shown to be cleaved and yielded proteins of the
correct size. Moreover, RHV1 E1E2 supported transduction
of hepatocytes when used to pseudotype lentivirus vectors.
Further studies will need to be carried out to find the specific
entry receptors, initially blocking CD81 and HCV entry
receptors and testing susceptibility of transduction in al-
ternative cell lines, but this initial experiment hints at the
hepatotropic potential of RHV1 in mice.
&e generation of viral pseudotypes is one of the most
widely used methods for assaying functional receptors,
allowing attachment, penetration, and uncoating to be
studied. &is study lays the groundwork for using RHV1
pseudotype particles to be used to asses these important
parts for the viral replication cycle and could also be used to
study cell tropism in a murine model and the antigenicity of
the functional E1 and E2 glycoproteins.
Our efforts to make an RHV and RPgV replication
competent model in vitro have so far proved unfruitful.
Using full-length viral constructs, we tested the human
hepatoma cell line (Huh-7.5) containing a MAVS
cleavage reporter where upon HCV NS3-4A cleavage of
the reporter, the RFP translocates to the nucleus [29].
Translocation of RFP was observed with full-length
RHV1, confirming the previous finding that the RHV1
NS3-4A protease is capable of cleaving human MAVS
[30]; however, the number of cells with RFP translocation
did not increase over time (Figure S3.A).
We further tested full-length viral constructs containing
m-Scarlet and BSD inserted between NS4A-B in both
Hepa1-6 and BHK-21, mScarlet was expressed in cells but
the number of cells expressing mScarlet did not increase
overtime and failed to yield a clone when selecting for
replication with BSD, even when expressing Sec14L2 and
ApoE, both essential for high levels of HCV replication
[31, 32] (Figure S3.B). Further cell lines could be tested along
with knocking out the innate immune response in future
experiments.
In Summary, this study shows that RHV1/2 and RPgV
contain IRESs that are capable of driving high levels of



































































Figure 4: Expression of RHV envelope proteins. Schematic of the RHV1 envelope expression vector and western blot of cell lysate at
48 h.p.t. from transfected HEK 293T (a) Intracellular immunofluorescence of 293Tcells at 48 h.p.t. with RHV1 envelope expression vector,
stained with flag tag in green, c-Myc tag in red, and combined with DAPI stain (b) Extracellular immunofluorescence for E2 by flag tag stain
(green) and combined withWGA (red) and DAPI (blue) from 293Tat 48 h.p.t. with RHV1 envelope expression vector, and images represent
one slice from z-stack (c) GFP-lentivirus vector pseudotyped with RHV or RHV1 envelope proteins or VSVG were incubated on Hepa1-6
cells; GFP positive cells indicate transduction (d).
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cellular proteases and can be used to pseudotype lentivirus
vectors that are capable of transducing murine hepatocytes.
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